Mannkind (MNKD) Change in Accured Expenses (2010 - 2026)
Mannkind's (MNKD) quarterly Change in Accured Expenses came in at -$5.8 million in Q1 2026, down 4406.72% year-on-year from $134000.0 in Q1 2025, and down 143.23% on a QoQ basis from $13.4 million in Q4 2025.
Mannkind (MNKD) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Mannkind (MNKD) has 17 years of Change in Accured Expenses data on file, last reported at -$5.8 million in Q1 2026.
- On a quarterly basis, Change in Accured Expenses fell 4406.72% year-over-year to -$5.8 million in Q1 2026; TTM through Mar 2026 was -$2.6 million, a 18.22% increase from a year earlier, with the FY2025 full-year figure at $3.3 million, up 220.46% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$5.8 million, down from $13.4 million in the prior quarter.
- Over the last five years, Change in Accured Expenses for MNKD reached as high as $13.4 million in Q4 2025 and fell as low as -$9.5 million in Q2 2025.
- Historically, Change in Accured Expenses has averaged $39117.6 across 5 years, with a median of -$644000.0 in 2022.
- Across the five-year window, Change in Accured Expenses surged 769.45% in 2023 and tumbled 4406.72% in 2026, its largest moves.
- Year by year, Change in Accured Expenses stood at -$1.6 million in 2022, then jumped by 769.45% to $10.4 million in 2023, then slumped by 79.81% to $2.1 million in 2024, then surged by 533.9% to $13.4 million in 2025, then sank by 143.23% to -$5.8 million in 2026.
- Per Business Quant data, the three most recent Change in Accured Expenses figures were -$5.8 million in Q1 2026, $13.4 million in Q4 2025, and -$761000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,011.97 Bn | 67,011.68 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 471.88 Bn | 467.08 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 122.20 Bn | 114.96 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.17 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.85 Bn | 50.67 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Mannkind | 1.25 Bn | 1.12 Bn | 82.66 Mn | -5.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.77 Mn |
| Mar 31, 2026 | -5.77 Mn |
| Dec 31, 2025 | 13.35 Mn |
| Dec 31, 2025 | 13.35 Mn |
| Sep 30, 2025 | -761,000.00 |
| Sep 30, 2025 | -761,000.00 |
| Jun 30, 2025 | -9.47 Mn |
| Jun 30, 2025 | -9.47 Mn |
| Mar 31, 2025 | 134,000.00 |
| Mar 31, 2025 | 134,000.00 |
| Dec 31, 2024 | 2.11 Mn |
| Dec 31, 2024 | 2.11 Mn |
| Sep 30, 2024 | -3.05 Mn |
| Sep 30, 2024 | -3.05 Mn |
| Jun 30, 2024 | -2.43 Mn |
| Jun 30, 2024 | -2.43 Mn |
| Mar 31, 2024 | 670,000.00 |
| Mar 31, 2024 | 670,000.00 |
| Dec 31, 2023 | 10.43 Mn |
| Dec 31, 2023 | 10.43 Mn |